Half-year report · Q2
8129.TEDINET S100URS6
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥755.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥1.48T | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥734.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥7.4bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥6.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥8.6bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥21.8bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.9bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥8.5bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥13.0bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥20.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥8.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥5.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥8.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥770.7bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥773.4bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥801.4bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥508.1bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥524.0bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥262.6bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥249.4bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥245.1bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥108.2bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥133.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥103.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥128.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥133.5bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥81.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥10.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥59.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥53.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥9.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥3.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥10.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥22.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥5.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥85.71 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥320.14 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥134.19 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥75.64 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥286.79 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥121.19 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 34.1% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.6% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥29.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥29.7bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.3bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥47.1bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥47.1bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥19m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥18m |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥442m |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥728.7bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥704.3bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥24.4bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥8.0bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.2bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥994m |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥203m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥784.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥755.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥29.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥8.6bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥29.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥29.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥46.6bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥46.6bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥7m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥895m |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥436m |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥709.4bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥684.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥24.6bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.3bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥678m |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥139m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥764.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥734.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥29.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥8.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 574
| Item | Context | Value | Unit |
|---|---|---|---|
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes uncertainties of entitys ability to continue as going concern quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding guarantee obligations (text) | CurrentQuarterInstant | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes financial instruments quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes securities quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes derivatives quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes business combinations quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |